Medetomidine in 70% of Philadelphia Drug Samples Makes Detox Harder

medetomidine philadelphia drug samples

Overdose deaths in Philadelphia, Pennsylvania have fallen to their lowest level in nearly a decade, yet people living with opioid addiction there say stopping has never been harder. The reason is medetomidine, a potent veterinary sedative that has spread through the city’s street drug supply since at least 2024.

A Street Supply That Keeps Changing

In Philadelphia, the word dope covers illicit drugs sold as opioids, often in small packets called stamp bags. What those packets contain has changed dramatically in recent years, according to reporting from WHYY News.

Fentanyl is a short-acting opioid. When used intravenously, most of its effects subside within an hour, according to the U.S. Food and Drug Administration, and withdrawal can begin as soon as the high fades.

Sedatives such as medetomidine and xylazine stretch that window, prolonging the high and delaying withdrawal symptoms by several hours, said Dr. Jamaal Shaban, a general surgeon who works with harm reduction organizations across the city.

The sedation is deep enough to confuse even experienced outreach workers. Anthony Kasper, who does outreach in Kensington, said that half the time you cannot tell whether someone is dying or just high.

Naloxone, sold as Narcan, reverses opioids but not medetomidine, which makes these overdoses harder to manage. Experts still urge bystanders to administer Narcan in every suspected opioid overdose, because the opioid component remains the part that stops breathing.

Medetomidine was present in around 70% of drug samples tested by the Philadelphia Department of Public Health in 2025, while xylazine appeared in 30% to 40%, according to a department report.

What Medetomidine Does to the Body

Medetomidine causes very low blood pressure, which can damage the kidneys. Withdrawal poses a different threat, including sustained elevated heart rate and blood pressure and a severe muscle breakdown that can also damage the kidneys, according to a 2026 Delaware Department of Health and Social Services report.

Sarah Laurel, founder of the Philadelphia and Delaware County recovery organization Savage Sisters, told WHYY that very young people who would historically have had no major health issues from drug use are arriving at hospitals with kidney failure.

A young person her organization helped recently died of kidney failure stemming from medetomidine use, many months after getting clean.

Why Standard Detox Falls Short

Dr. Jason Wallach, a chemist who runs St. Joseph’s University’s pharmacology lab, called it an exceptionally violent detox process. Current detox procedures, Shaban said, do not adequately address patients dependent on the city’s present dope blend.

Thomas Harris, who has used dope for years, described the gap from the inside. Clinics and hospitals treat for opioids, he said, not medetomidine. A sedative called dexmedetomidine, sold as Precedex, can counter some of the most dangerous withdrawal symptoms, but it generally must be given intravenously under close supervision, often in an intensive care unit.

Philadelphia health officials have issued guidance recommending that providers use dexmedetomidine and clonidine to treat medetomidine withdrawal.

Dr. Jeanmarie Perrone, an emergency physician and founding director at the Penn Medicine Center for Addiction Medicine and Policy, said hospitals can stabilize patients in withdrawal but there is no established system for helping them recover from dependence on the drug.

Shaban’s view is blunt: detox cannot be a five-day event anymore and needs to last at least two weeks, because the severity of this withdrawal drives relapse rates higher.

Other hazards are entering the supply too. Local anesthetics, which mimic the numbing sensation of injected opioids and can cause a potentially fatal toxicity at large doses, are increasingly common, and highly potent synthetic opioids called nitazenes have appeared in Philadelphia since at least 2022.

What Is Driving the Shift

Several experts interviewed by WHYY pointed to enforcement policy. Hamilton Morris, a researcher and journalist, cited the Iron Law of Prohibition, the theory that stricter enforcement pushes traffickers toward more potent substances.

Pennsylvania classified xylazine as a Schedule III controlled substance in 2024, and medetomidine began appearing in Philadelphia’s supply that same year.

The DEA’s Philadelphia division disputes that framing. Assistant Special Agent in Charge Joshua Romig argued economics play a larger role, pointing to trafficking organizations replacing heroin with fentanyl to undercut competitors.

Research published this year in the Journal of the American Medical Association found that supply-side fentanyl seizures in China led to an overall reduction of U.S. overdose deaths.

Finding Help for Opioid Addiction in Philadelphia, Pennsylvania

For anyone fighting opioid addiction in Philadelphia, medication-assisted treatment with methadone or buprenorphine remains the evidence-based standard regardless of what is mixed into the supply.

NA meetings in Philadelphia offer free peer support every day, in person and online, and harm reduction programs across the city distribute naloxone and drug checking supplies.

Narcotics.com maintains a directory of NA meetings and opioid treatment programs in Philadelphia, Pennsylvania and nationwide. Get in contact with a treatment advisor by calling 800-934-1582(Sponsored) .

the Take-Away

Overdose deaths in Philadelphia, Pennsylvania have fallen to their lowest level in nearly a decade, yet people living with opioid addiction there say stopping has never been harder. The reason is medetomidine, a potent veterinary sedative that has spread through the city’s street drug supply since at least 2024. A Street Supply That Keeps Changing …